Top India Stock Picks From Jefferies Across Key Sectors

Jefferies highlighted 7 India sector picks, emphasizing growth catalysts and execution: JSW Energy targets capacity rising 1.8x to 24.7 GW by FY30E, with EBITDA CAGR of 17% and net debt/EBITDA falling to 5.0x (from 6.7x). Other key calls include Navin Fluorine’s 23% revenue CAGR (31% EBITDA margin; price target Rs9,045) and Fortis Healthcare’s bed expansion plus IHH stake increase to 51% (price target Rs1,125). Overall, the note is broadly constructive with multiple valuation price targets (e.g., Zomato-led Eternal Rs415; Gland Pharma Rs3,350; Tata Consumer Products Rs1,450; Lodha/ Macrotech data-center lease income target Rs20B).

Analysis

The cleanest tradable signal here is not the India stock-picking itself but the lower-rate backdrop. That matters most for long-duration equities like AMZN and FTS: a further 50-100 bp decline in yields can expand multiples faster than near-term earnings changes, especially for businesses where terminal value does the heavy lifting. For AMZN, the India data-center angle is still optionality rather than current P&L, but it reinforces AWS’ ability to place incremental capacity where power and land are becoming constraints.

CC is the most interesting second-order beneficiary because immersion cooling is one of the few credible ways to reduce power intensity in AI/data-center buildouts. The risk is adoption stays pilot-scale and gets competed away by bundled solutions from larger HVAC/cooling players; I would only lean in if we see repeat orders over the next 1-2 quarters. BAYRY has a cleaner earnings bridge via a protected oncology asset, but the stock remains a hostage to the broader litigation/portfolio overhang, so the patent runway helps more on downside defense than on a clean rerating.

Contrarian view: the market may be overpaying for execution stories that are not yet cash-flow visible. In leveraged sectors, financing access is the real catalyst; if yields back up or credit spreads widen, the highly levered growth names will lag even if the operating narrative stays intact. TGT is the odd one out here: lower commodity input costs are helpful, but the margin benefit looks too incremental to drive a meaningful re-rate unless demand also improves.

Key Decisions for Investors

• Long FTS on any pullback as a rates-sensitive utility proxy; 3-6 month horizon. Risk/reward is favorable if the yield slide persists; falsifier is a sharp backup in long-end yields that re-prices defensive duration.
• Small-size long CC, ideally on confirmation of commercial data-center design wins; use a 6-12 month horizon. Better via call spread than outright leverage because the adoption curve may be lumpy; invalidate if the next two quarters do not show backlog conversion.
• Buy BAYRY only as a catalyst-driven position ahead of the next oncology update, preferably via a call spread to limit litigation downside. Upside depends on Nubeqa growth translating into visible guidance support; if that growth decelerates, exit.
• No active trade in TGT yet; keep it on watch for gross-margin inflection from cheaper coffee/commodities. If the next print does not show margin expansion, the input-cost tailwind is likely already in the price.